Mendaera

Focalist combines a handheld robotic device with real-time ultrasound imaging to guide needle placement during procedures such as biopsies and vascular access. The system aims to automate the precision component that normally requires years of clinician training, making image-guided interventions reproducible by a broader range of healthcare providers. It received FDA clearance and has been used in live clinical procedures, per the company.

Rather than a multi-arm console anchored in a dedicated operating room, Focalist is a handheld instrument designed for portability and point-of-care use. The architecture targets the manual dexterity challenge of needle guidance — not large-incision surgery — and is intended to integrate into existing clinical workflows without requiring capital-intensive infrastructure. Its adoption path competes against the training bottleneck in ultrasound-guided procedures rather than against other robotics capital-equipment purchases.

Mendaera announced FDA clearance for the Focalist platform, marking the shift from development to commercial use in the United States. The company subsequently reported the world's first procedures performed with the system, establishing clinical-use evidence in live patient settings. No other geographic regulatory approvals have been disclosed publicly.

The firm's website displays logos of institutional investors described as 'Investors that power progress,' but Mendaera does not name individual backers, disclose funding round details, or publish capitalization figures. No public regulatory filings revealing the capital structure are currently available, leaving the investor syndicate unconfirmed.

The company's website invites healthcare providers and potential customers to sign up for updates, exclusive demos, and early opportunities, suggesting an active but early-stage commercial rollout. Mendaera also directs existing customers to contact support for Instructions for Use documentation, indicating that some units are already in clinical use. Pricing and distribution models have not been publicly disclosed.